An Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Treatment-Naïve and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 23 Jul 2018
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 13 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 28 Feb 2018 Planned End Date changed from 26 Feb 2019 to 8 Mar 2018.
- 09 Oct 2017 Planned End Date changed from 27 Feb 2019 to 18 Feb 2019.